{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T13:14:58Z","timestamp":1790082898745,"version":"4.0.1"},"reference-count":59,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2025,12,24]],"date-time":"2025-12-24T00:00:00Z","timestamp":1766534400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,12,24]],"date-time":"2025-12-24T00:00:00Z","timestamp":1766534400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["CE 281\/6-1"],"award-info":[{"award-number":["CE 281\/6-1"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100009708","name":"Novo Nordisk Fonden","doi-asserted-by":"publisher","award":["0066909"],"award-info":[{"award-number":["0066909"]}],"id":[{"id":"10.13039\/501100009708","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008363","name":"Kr\u00e6ftens Bek\u00e6mpelse","doi-asserted-by":"publisher","award":["A18859"],"award-info":[{"award-number":["A18859"]}],"id":[{"id":"10.13039\/100008363","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Interdisciplinary Center for Clinical Research of the University of Erlangen-Nuremberg"},{"DOI":"10.13039\/501100003554","name":"Lundbeckfonden","doi-asserted-by":"publisher","award":["R380-2021-1264"],"award-info":[{"award-number":["R380-2021-1264"]}],"id":[{"id":"10.13039\/501100003554","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Br J Cancer"],"published-print":{"date-parts":[[2026,3,5]]},"DOI":"10.1038\/s41416-025-03282-0","type":"journal-article","created":{"date-parts":[[2025,12,24]],"date-time":"2025-12-24T11:51:55Z","timestamp":1766577115000},"page":"799-810","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Pan-cancer analysis of pyrimidine metabolism reveals signaling pathways connections with chemoresistance role"],"prefix":"10.1038","volume":"134","author":[{"given":"Vignesh","family":"Ramesh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mert","family":"Demirdizen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luisa","family":"Pinna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas Koed","family":"Doktor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federica","family":"Benso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4308-3398","authenticated-orcid":false,"given":"Mohammad Aarif","family":"Siddiqui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3632-8476","authenticated-orcid":false,"given":"Paolo","family":"Ceppi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,24]]},"reference":[{"key":"3282_CR1","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","volume":"144","author":"D Hanahan","year":"2011","unstructured":"Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144:646\u201374.","journal-title":"Cell"},{"key":"3282_CR2","first-page":"209","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71:209\u201349.","journal-title":"CA Cancer J Clin"},{"key":"3282_CR3","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-023-04292-3","volume":"21","author":"G Dagar","year":"2023","unstructured":"Dagar G, Gupta A, Masoodi T, Nisar S, Merhi M, Hashem S, et al. Harnessing the potential of CAR-T cell therapy: progress, challenges, and future directions in hematological and solid tumor treatments. J Transl Med. 2023;21:449.","journal-title":"J Transl Med"},{"key":"3282_CR4","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1038\/s41392-022-01136-2","volume":"7","author":"DR Wang","year":"2022","unstructured":"Wang DR, Wu XL, Sun YL. Therapeutic targets and biomarkers of tumor immunotherapy: response versus non-response. Signal Transduct Target Ther. 2022;7:331.","journal-title":"Signal Transduct Target Ther"},{"key":"3282_CR5","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1056\/NEJMoa1913662","volume":"382","author":"SS Ramalingam","year":"2020","unstructured":"Ramalingam SS, Vansteenkiste J, Planchard D, Cho BC, Gray JE, Ohe Y, et al. Overall survival with osimertinib in untreated, EGFR-mutated advanced NSCLC. N Engl J Med. 2020;382:41\u201350.","journal-title":"N Engl J Med"},{"key":"3282_CR6","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1016\/j.jtho.2021.12.005","volume":"17","author":"S Caini","year":"2022","unstructured":"Caini S, Del Riccio M, Vettori V, Scotti V, Martinoli C, Raimondi S, et al. Quitting smoking at or around diagnosis improves the overall survival of lung cancer patients: a systematic review and meta-analysis. J Thorac Oncol. 2022;17:623\u201336.","journal-title":"J Thorac Oncol"},{"key":"3282_CR7","first-page":"1975","volume-title":"SEER Cancer Statistics Review","author":"N Howlader","year":"2020","unstructured":"Howlader N, Noone A, Krapcho M, Miller D, Brest A, Yu M et al. SEER Cancer Statistics Review. Bethesda, MD: National Cancer Institute; 2020. pp. 1975\u20132017."},{"key":"3282_CR8","doi-asserted-by":"crossref","unstructured":"Ramos A, Sadeghi S, Tabatabaeian H. Battling chemoresistance in cancer: root causes and strategies to uproot them. Int J Mol Sci. 2021;22:9451.","DOI":"10.3390\/ijms22179451"},{"key":"3282_CR9","doi-asserted-by":"crossref","unstructured":"Bukowski K, Kciuk M, Kontek R. Mechanisms of multidrug resistance in cancer chemotherapy. Int J Mol Sci. 2020;21:3233.","DOI":"10.3390\/ijms21093233"},{"key":"3282_CR10","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1038\/s41568-023-00557-7","volume":"23","author":"NJ Mullen","year":"2023","unstructured":"Mullen NJ, Singh PK. Nucleotide metabolism: a pan-cancer metabolic dependency. Nat Rev Cancer. 2023;23:275\u201394.","journal-title":"Nat Rev Cancer"},{"key":"3282_CR11","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1007\/s11302-020-09711-4","volume":"16","author":"H Wang","year":"2020","unstructured":"Wang H, Wang X, Xu L, Zhang J, Cao H. High expression levels of pyrimidine metabolic rate-limiting enzymes are adverse prognostic factors in lung adenocarcinoma: a study based on The Cancer Genome Atlas and Gene Expression Omnibus datasets. Purinergic Signal. 2020;16:347\u201366.","journal-title":"Purinergic Signal"},{"key":"3282_CR12","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.1056680","volume":"13","author":"Y Luo","year":"2022","unstructured":"Luo Y, Tian W, Lu X, Zhang C, Xie J, Deng X, et al. Prognosis stratification in breast cancer and characterization of immunosuppressive microenvironment through a pyrimidine metabolism-related signature. Front Immunol. 2022;13:1056680.","journal-title":"Front Immunol"},{"key":"3282_CR13","doi-asserted-by":"publisher","DOI":"10.1186\/s12935-021-02385-x","volume":"21","author":"Z Wu","year":"2021","unstructured":"Wu Z, Tan J, Zhuang Y, Zhong M, Xiong Y, Ma J, et al. Identification of crucial genes of pyrimidine metabolism as biomarkers for gastric cancer prognosis. Cancer Cell Int. 2021;21:668.","journal-title":"Cancer Cell Int"},{"key":"3282_CR14","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.684961","volume":"11","author":"W Wang","year":"2021","unstructured":"Wang W, Cui J, Ma H, Lu W, Huang J. Targeting pyrimidine metabolism in the era of precision cancer medicine. Front Oncol. 2021;11:684961.","journal-title":"Front Oncol"},{"key":"3282_CR15","doi-asserted-by":"publisher","first-page":"1559","DOI":"10.1016\/j.cell.2018.07.019","volume":"174","author":"JS Lee","year":"2018","unstructured":"Lee JS, Adler L, Karathia H, Carmel N, Rabinovich S, Auslander N, et al. Urea cycle dysregulation generates clinically relevant genomic and biochemical signatures. Cell. 2018;174:1559\u201370.e22.","journal-title":"Cell"},{"key":"3282_CR16","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1002\/path.4897","volume":"242","author":"A Siddiqui","year":"2017","unstructured":"Siddiqui A, Vazakidou ME, Schwab A, Napoli F, Fernandez-Molina C, Rapa I, et al. Thymidylate synthase is functionally associated with ZEB1 and contributes to the epithelial-to-mesenchymal transition of cancer cells. J Pathol. 2017;242:221\u201333.","journal-title":"J Pathol"},{"key":"3282_CR17","doi-asserted-by":"publisher","first-page":"2223","DOI":"10.1038\/s41418-019-0289-6","volume":"26","author":"A Siddiqui","year":"2019","unstructured":"Siddiqui A, Gollavilli PN, Schwab A, Vazakidou ME, Ersan PG, Ramakrishnan M, et al. Thymidylate synthase maintains the de-differentiated state of triple negative breast cancers. Cell Death Differ. 2019;26:2223\u201336.","journal-title":"Cell Death Differ"},{"key":"3282_CR18","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1038\/s41416-020-01095-x","volume":"124","author":"MA Siddiqui","year":"2021","unstructured":"Siddiqui MA, Gollavilli PN, Ramesh V, Parma B, Schwab A, Vazakidou ME, et al. Thymidylate synthase drives the phenotypes of epithelial-to-mesenchymal transition in non-small cell lung cancer. Br J Cancer. 2021;124:281\u20139.","journal-title":"Br J Cancer"},{"key":"3282_CR19","doi-asserted-by":"crossref","unstructured":"Yamaguchi N, Weinberg EM, Nguyen A, Liberti MV, Goodarzi H, Janjigian YY, et al. PCK1 and DHODH drive colorectal cancer liver metastatic colonization and hypoxic growth by promoting nucleotide synthesis. Elife. 2019;8:e52135.","DOI":"10.7554\/eLife.52135"},{"key":"3282_CR20","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1158\/2159-8290.CD-16-0611","volume":"7","author":"KK Brown","year":"2017","unstructured":"Brown KK, Spinelli JB, Asara JM, Toker A. Adaptive reprogramming of de novo pyrimidine synthesis is a metabolic vulnerability in triple-negative breast cancer. Cancer Discov. 2017;7:391\u20139.","journal-title":"Cancer Discov"},{"key":"3282_CR21","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1016\/j.cell.2018.03.035","volume":"173","author":"F Sanchez-Vega","year":"2018","unstructured":"Sanchez-Vega F, Mina M, Armenia J, Chatila WK, Luna A, La KC, et al. Oncogenic signaling pathways in the cancer genome atlas. Cell. 2018;173:321\u201337.e10.","journal-title":"Cell"},{"key":"3282_CR22","doi-asserted-by":"publisher","first-page":"1465","DOI":"10.1016\/j.cell.2019.08.018","volume":"178","author":"D Demircio\u011flu","year":"2019","unstructured":"Demircio\u011flu D, Cukuroglu E, Kindermans M, Nandi T, Calabrese C, Fonseca NA, et al. A pan-cancer transcriptome analysis reveals pervasive regulation through alternative promoters. Cell. 2019;178:1465\u201377.e17.","journal-title":"Cell"},{"key":"3282_CR23","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1111\/jcmm.14746","volume":"24","author":"FG Frost","year":"2020","unstructured":"Frost FG, Cherukuri PF, Milanovich S, Boerkoel CF. Pan-cancer RNA-seq data stratifies tumours by some hallmarks of cancer. J Cell Mol Med. 2020;24:418\u201330.","journal-title":"J Cell Mol Med"},{"key":"3282_CR24","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-022-09371-0","volume":"22","author":"A F\u00e4ldt Beding","year":"2022","unstructured":"F\u00e4ldt Beding A, Larsson P, Helou K, Einbeigi Z, Parris TZ. Pan-cancer analysis identifies BIRC5 as a prognostic biomarker. BMC Cancer. 2022;22:322.","journal-title":"BMC Cancer"},{"key":"3282_CR25","doi-asserted-by":"crossref","unstructured":"Thennavan A, Beca F, Xia Y, Recio SG, Allison K, Collins LC, et al. Molecular analysis of TCGA breast cancer histologic types. Cell Genom. 2021;1:100067.","DOI":"10.1016\/j.xgen.2021.100067"},{"key":"3282_CR26","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1038\/nature13480","volume":"513","author":"AJ Bass","year":"2014","unstructured":"Bass AJ, Thorsson V, Shmulevich I, Reynolds SM, Miller M, Bernard B, et al. Comprehensive molecular characterization of gastric adenocarcinoma. Nature. 2014;513:202\u20139.","journal-title":"Nature"},{"key":"3282_CR27","doi-asserted-by":"publisher","first-page":"W488","DOI":"10.1093\/nar\/gkaa216","volume":"48","author":"A Ianevski","year":"2020","unstructured":"Ianevski A, Giri AK, Aittokallio T. SynergyFinder 2.0: visual analytics of multi-drug combination synergies. Nucleic Acids Res. 2020;48:W488\u2013w93.","journal-title":"Nucleic Acids Res"},{"key":"3282_CR28","doi-asserted-by":"crossref","unstructured":"Ramesh V, Gollavilli PN, Pinna L, Siddiqui MA, Turtos AM, Napoli F, et al. Propionate reinforces epithelial identity and reduces aggressiveness of lung carcinoma. EMBO Mol Med. 2023;15:e17836.","DOI":"10.15252\/emmm.202317836"},{"key":"3282_CR29","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1038\/s41586-019-1103-9","volume":"568","author":"FM Behan","year":"2019","unstructured":"Behan FM, Iorio F, Picco G, Gon\u00e7alves E, Beaver CM, Migliardi G, et al. Prioritization of cancer therapeutic targets using CRISPR-Cas9 screens. Nature. 2019;568:511\u20136.","journal-title":"Nature"},{"key":"3282_CR30","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-09695-9","volume":"10","author":"K Ortmayr","year":"2019","unstructured":"Ortmayr K, Dubuis S, Zampieri M. Metabolic profiling of cancer cells reveals genome-wide crosstalk between transcriptional regulators and metabolism. Nat Commun. 2019;10:1841.","journal-title":"Nat Commun"},{"key":"3282_CR31","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/j.cell.2016.08.057","volume":"167","author":"DB Sykes","year":"2016","unstructured":"Sykes DB, Kfoury YS, Mercier FE, Wawer MJ, Law JM, Haynes MK, et al. Inhibition of dihydroorotate dehydrogenase overcomes differentiation blockade in acute myeloid leukemia. Cell. 2016;167:171\u201386.e15.","journal-title":"Cell"},{"key":"3282_CR32","doi-asserted-by":"crossref","unstructured":"Mullen NJ, Shukla SK, Thakur R, Kollala SS, Wang D, Chaika N, et al. DHODH inhibition enhances the efficacy of immune checkpoint blockade by increasing cancer cell antigen presentation. Elife. 2024;12:RP87292.","DOI":"10.7554\/eLife.87292.3"},{"key":"3282_CR33","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1038\/s41588-023-01339-5","volume":"55","author":"W Mannherz","year":"2023","unstructured":"Mannherz W, Agarwal S. Thymidine nucleotide metabolism controls human telomere length. Nat Genet. 2023;55:568\u201380.","journal-title":"Nat Genet"},{"key":"3282_CR34","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1016\/j.chembiol.2018.03.005","volume":"25","author":"M Koundinya","year":"2018","unstructured":"Koundinya M, Sudhalter J, Courjaud A, Lionne B, Touyer G, Bonnet L, et al. Dependence on the pyrimidine biosynthetic enzyme DHODH is a synthetic lethal vulnerability in mutant KRAS-driven cancers. Cell Chem Biol. 2018;25:705\u201317.e11.","journal-title":"Cell Chem Biol"},{"key":"3282_CR35","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-020-03044-1","volume":"11","author":"Y Qian","year":"2020","unstructured":"Qian Y, Liang X, Kong P, Cheng Y, Cui H, Yan T, et al. Elevated DHODH expression promotes cell proliferation via stabilizing \u03b2-catenin in esophageal squamous cell carcinoma. Cell Death Dis. 2020;11:862.","journal-title":"Cell Death Dis"},{"key":"3282_CR36","doi-asserted-by":"publisher","first-page":"12828","DOI":"10.1073\/pnas.0910885107","volume":"107","author":"AA Khutornenko","year":"2010","unstructured":"Khutornenko AA, Roudko VV, Chernyak BV, Vartapetian AB, Chumakov PM, Evstafieva AG. Pyrimidine biosynthesis links mitochondrial respiration to the p53 pathway. Proc Natl Acad Sci USA. 2010;107:12828\u201333.","journal-title":"Proc Natl Acad Sci USA"},{"key":"3282_CR37","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1016\/j.cmet.2018.10.014","volume":"29","author":"M Bajzikova","year":"2019","unstructured":"Bajzikova M, Kovarova J, Coelho AR, Boukalova S, Oh S, Rohlenova K, et al. Reactivation of dihydroorotate dehydrogenase-driven pyrimidine biosynthesis restores tumor growth of respiration-deficient cancer cells. Cell Metab. 2019;29:399\u2013416.e10.","journal-title":"Cell Metab"},{"key":"3282_CR38","doi-asserted-by":"crossref","unstructured":"Ariav Y, Ch\u2019ng JH, Christofk HR, Ron-Harel N, Erez A. Targeting nucleotide metabolism as the nexus of viral infections, cancer, and the immune response. Sci Adv. 2021;7:eabg6165.","DOI":"10.1126\/sciadv.abg6165"},{"key":"3282_CR39","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1038\/s41392-020-00235-2","volume":"5","author":"Y Dong","year":"2020","unstructured":"Dong Y, Tu R, Liu H, Qing G. Regulation of cancer cell metabolism: oncogenic MYC in the driver\u2019s seat. Signal Transduct Target Ther. 2020;5:124.","journal-title":"Signal Transduct Target Ther"},{"key":"3282_CR40","doi-asserted-by":"publisher","first-page":"2392","DOI":"10.4161\/cc.6390","volume":"7","author":"S Mannava","year":"2008","unstructured":"Mannava S, Grachtchouk V, Wheeler LJ, Im M, Zhuang D, Slavina EG, et al. Direct role of nucleotide metabolism in C-MYC-dependent proliferation of melanoma cells. Cell Cycle. 2008;7:2392\u2013400.","journal-title":"Cell Cycle"},{"key":"3282_CR41","doi-asserted-by":"publisher","first-page":"2529","DOI":"10.1128\/MCB.17.5.2529","volume":"17","author":"KE Boyd","year":"1997","unstructured":"Boyd KE, Farnham PJ. Myc versus USF: discrimination at the cad gene is determined by core promoter elements. Mol Cell Biol. 1997;17:2529\u201337.","journal-title":"Mol Cell Biol"},{"key":"3282_CR42","doi-asserted-by":"publisher","first-page":"e2722","DOI":"10.1371\/journal.pone.0002722","volume":"3","author":"YC Liu","year":"2008","unstructured":"Liu YC, Li F, Handler J, Huang CR, Xiang Y, Neretti N, et al. Global regulation of nucleotide biosynthetic genes by c-Myc. PLoS One. 2008;3:e2722.","journal-title":"PLoS One"},{"key":"3282_CR43","doi-asserted-by":"publisher","DOI":"10.1016\/j.tice.2023.102096","volume":"82","author":"D Ren","year":"2023","unstructured":"Ren D, Li L, Wang S, Zuo Y. The c-MYC transcription factor conduces to resistance to cisplatin by regulating MMS19 in bladder cancer cells. Tissue Cell. 2023;82:102096.","journal-title":"Tissue Cell"},{"key":"3282_CR44","doi-asserted-by":"publisher","DOI":"10.1016\/j.drup.2022.100909","volume":"66","author":"Y Di","year":"2023","unstructured":"Di Y, Jing X, Hu K, Wen X, Ye L, Zhang X, et al. The c-MYC-WDR43 signalling axis promotes chemoresistance and tumour growth in colorectal cancer by inhibiting p53 activity. Drug Resist Updat. 2023;66:100909.","journal-title":"Drug Resist Updat"},{"key":"3282_CR45","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-017-01967-6","volume":"8","author":"AS Farrell","year":"2017","unstructured":"Farrell AS, Joly MM, Allen-Petersen BL, Worth PJ, Lanciault C, Sauer D, et al. MYC regulates ductal-neuroendocrine lineage plasticity in pancreatic ductal adenocarcinoma associated with poor outcome and chemoresistance. Nat Commun. 2017;8:1728.","journal-title":"Nat Commun"},{"key":"3282_CR46","doi-asserted-by":"publisher","first-page":"4514","DOI":"10.1158\/0008-5472.CAN-19-3971","volume":"80","author":"YA Shen","year":"2020","unstructured":"Shen YA, Hong J, Asaka R, Asaka S, Hsu FC, Suryo Rahmanto Y, et al. Inhibition of the MYC-regulated glutaminase metabolic axis is an effective synthetic lethal approach for treating chemoresistant ovarian cancers. Cancer Res. 2020;80:4514\u201326.","journal-title":"Cancer Res"},{"key":"3282_CR47","doi-asserted-by":"publisher","first-page":"2260","DOI":"10.1158\/1535-7163.MCT-14-0801","volume":"14","author":"JM Reyes-Gonz\u00e1lez","year":"2015","unstructured":"Reyes-Gonz\u00e1lez JM, Armaiz-Pe\u00f1a GN, Mangala LS, Valiyeva F, Ivan C, Pradeep S, et al. Targeting c-MYC in platinum-resistant ovarian cancer. Mol Cancer Ther. 2015;14:2260\u20139.","journal-title":"Mol Cancer Ther"},{"key":"3282_CR48","doi-asserted-by":"publisher","first-page":"6314","DOI":"10.1073\/pnas.0802080105","volume":"105","author":"K Hastak","year":"2008","unstructured":"Hastak K, Paul RK, Agarwal MK, Thakur VS, Amin AR, Agrawal S, et al. DNA synthesis from unbalanced nucleotide pools causes limited DNA damage that triggers ATR-CHK1-dependent p53 activation. Proc Natl Acad Sci USA. 2008;105:6314\u20139.","journal-title":"Proc Natl Acad Sci USA"},{"key":"3282_CR49","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-03441-3","volume":"9","author":"M Ladds","year":"2018","unstructured":"Ladds M, van Leeuwen IMM, Drummond CJ, Chu S, Healy AR, Popova G, et al. A DHODH inhibitor increases p53 synthesis and enhances tumor cell killing by p53 degradation blockage. Nat Commun. 2018;9:1107.","journal-title":"Nat Commun"},{"key":"3282_CR50","doi-asserted-by":"publisher","DOI":"10.1016\/j.mbplus.2020.100021","volume":"6-7","author":"S Liot","year":"2020","unstructured":"Liot S, Aubert A, Hervieu V, Kholti NE, Schalkwijk J, Verrier B, et al. Loss of Tenascin-X expression during tumor progression: a new pan-cancer marker. Matrix Biol. 2020;6-7:100021.","journal-title":"Matrix Biol"},{"key":"3282_CR51","doi-asserted-by":"publisher","first-page":"1360","DOI":"10.1038\/bjc.2017.291","volume":"117","author":"T Murakami","year":"2017","unstructured":"Murakami T, Kikuchi H, Ishimatsu H, Iino I, Hirotsu A, Matsumoto T, et al. Tenascin C in colorectal cancer stroma is a predictive marker for liver metastasis and is a potent target of miR-198 as identified by microRNA analysis. Br J Cancer. 2017;117:1360\u201370.","journal-title":"Br J Cancer"},{"key":"3282_CR52","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2022.215837","volume":"549","author":"D He","year":"2022","unstructured":"He D, Chen M, Chang L, Gu J, Liu F, Gao X, et al. De novo pyrimidine synthesis fuels glycolysis and confers chemoresistance in gastric cancer. Cancer Lett. 2022;549:215837.","journal-title":"Cancer Lett"},{"key":"3282_CR53","doi-asserted-by":"publisher","first-page":"1232","DOI":"10.1053\/j.gastro.2023.02.025","volume":"164","author":"X Jiang","year":"2023","unstructured":"Jiang X, Ma Y, Wang T, Zhou H, Wang K, Shi W, et al. Targeting UBE2T potentiates gemcitabine efficacy in pancreatic cancer by regulating pyrimidine metabolism and replication stress. Gastroenterology. 2023;164:1232\u201347.","journal-title":"Gastroenterology"},{"key":"3282_CR54","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1038\/onc.2016.195","volume":"36","author":"LY Chiu","year":"2017","unstructured":"Chiu LY, Hsin IL, Yang TY, Sung WW, Chi JY, Chang JT, et al. The ERK-ZEB1 pathway mediates epithelial-mesenchymal transition in pemetrexed resistant lung cancer cells with suppression by vinca alkaloids. Oncogene. 2017;36:242\u201353.","journal-title":"Oncogene"},{"key":"3282_CR55","doi-asserted-by":"publisher","DOI":"10.1016\/j.molmet.2020.02.005","volume":"35","author":"A Siddiqui","year":"2020","unstructured":"Siddiqui A, Ceppi P. A non-proliferative role of pyrimidine metabolism in cancer. Mol Metab. 2020;35:100962.","journal-title":"Mol Metab"},{"key":"3282_CR56","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2022.114176","volume":"232","author":"L Zhang","year":"2022","unstructured":"Zhang L, Zhang J, Wang J, Ren C, Tang P, Ouyang L, et al. Recent advances of human dihydroorotate dehydrogenase inhibitors for cancer therapy: current development and future perspectives. Eur J Med Chem. 2022;232:114176.","journal-title":"Eur J Med Chem"},{"key":"3282_CR57","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/j.pharmthera.2018.10.012","volume":"195","author":"JT Madak","year":"2019","unstructured":"Madak JT, Bankhead A 3rd, Cuthbertson CR, Showalter HD, Neamati N. Revisiting the role of dihydroorotate dehydrogenase as a therapeutic target for cancer. Pharm Ther. 2019;195:111\u201331.","journal-title":"Pharm Ther"},{"key":"3282_CR58","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.biopha.2018.11.010","volume":"110","author":"MS Dorasamy","year":"2019","unstructured":"Dorasamy MS, Ab A, Nellore K, Wong PF. Synergistic inhibition of melanoma xenografts by Brequinar sodium and Doxorubicin. Biomed Pharmacother. 2019;110:29\u201336.","journal-title":"Biomed Pharmacother"},{"key":"3282_CR59","doi-asserted-by":"crossref","unstructured":"Muhammad N, Lee HM, Kim J. Oncology therapeutics targeting the metabolism of amino acids. Cells. 2020;9:1904.","DOI":"10.3390\/cells9081904"}],"container-title":["British Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41416-025-03282-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41416-025-03282-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41416-025-03282-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T10:03:47Z","timestamp":1770977027000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41416-025-03282-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,24]]},"references-count":59,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,3,5]]}},"alternative-id":["3282"],"URL":"https:\/\/doi.org\/10.1038\/s41416-025-03282-0","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2023.12.06.570388","asserted-by":"object"}]},"ISSN":["0007-0920","1532-1827"],"issn-type":[{"value":"0007-0920","type":"print"},{"value":"1532-1827","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,24]]},"assertion":[{"value":"10 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 November 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 November 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 December 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"All authors have reviewed the manuscript prior to submission and have provided their consent for publication.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}]}}